Stocks
Incyte’s Monjuvi Lifts Lymphoma Survival 25% in Late-Stage Trial
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...